Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma.

ABSTRACT:

Background

Inflammation can modulate tumour growth and progression, and influence clinical response to treatment. We investigated the potential of circulating inflammatory proteins for response stratification of immune checkpoint inhibitor (ICI) therapy for advanced melanoma.

Methods

Study subjects were 87 patients with unresectable stage III or IV cutaneous melanoma from the multiple centres across the United Kingdom (UK) and the Netherlands (NL) who received ipilimumab, nivolumab, or pembrolizumab, or a combination of ipilimumab and nivolumab. Serum samples were collected before and during ICI therapy at follow-up visits scheduled every third week over a 12-week period. We performed targeted quantification of 92 proteins involved in inflammation and tested for association

SUBMITTER: Rossi N 

PROVIDER: S-EPMC9421308 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature